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Abstract We review current pharmacological treatments
for peripheral and central vestibular disorders, and ocular
motor disorders that impair vision, especially pathological
nystagmus. The prerequisites for successful pharmaco-
therapy of vertigo, dizziness, and abnormal eye movements
are the ‘‘4 D’s’’: correct diagnosis, correct drug, appro-
priate dosage, and sufﬁcient duration. There are seven
groups of drugs (the ‘‘7 A’s’’) that can be used: antiemet-
ics; anti-inﬂammatory, anti-Me ´nie `re’s, and anti-migrainous
medications; anti-depressants, anti-convulsants, and am-
inopyridines. A recovery from acute vestibular neuritis can
be promoted by treatment with oral corticosteroids. Beta-
histine may reduce the frequency of attacks of Me ´nie `re’s
disease. The aminopyridines constitute a novel treatment
approach for downbeat and upbeat nystagmus, as well as
episodic ataxia type 2 (EA 2); these drugs may restore
normal ‘‘pacemaker’’ activity to the Purkinje cells that
govern vestibular and cerebellar nuclei. A limited number
of trials indicate that baclofen improves periodic alternat-
ing nystagmus, and that gabapentin and memantine
improve acquired pendular and infantile (congenital) nys-
tagmus. Preliminary reports suggest suppression of square-
wave saccadic intrusions by memantine, and ocular ﬂutter
by beta-blockers. Thus, although progress has been made in
the treatment of vestibular neuritis, some forms of patho-
logical nystagmus, and EA 2, controlled, masked trials are
still needed to evaluate treatments for many vestibular and
ocular motor disorders, including betahistine for Me ´nie `re’s
disease, oxcarbazepine for vestibular paroxysmia, or
metoprolol for vestibular migraine.
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Introduction
Vertigo and dizziness arise from many multisensory and
sensorimotor syndromes of various etiologies and pathog-
eneses, which are best elucidated using an interdisciplinary
approach. After headache, vertigo is one of the most fre-
quent presenting symptoms to physicians in many disci-
plines, with a life-time prevalence of almost 30% [1]. Here,
we ﬁrst review current pharmacological treatments for
common peripheral and central vestibular disorders (for
description of other therapies, see reviews [2, 3]). Second,
we focus on those ocular oscillations that impair vision and
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(oscillopsia). In particular, the pathophysiology, topo-
graphic diagnosis, and current pharmacological treatment
of downbeat nystagmus (DBN), upbeat nystagmus (UBN),
acquired pendular nystagmus (APN), and saccadic oscil-
lations that impair vision (for description of other therapies,
see reviews [4–7]) are discussed.
Rationale for pharmacotherapy of vertigo, dizziness,
and ocular motor disorders impairing vision
The prerequisites for successful pharmacological treatment
of vertigo, dizziness, ocular motor disorders, and patho-
logical nystagmus are the ‘‘4 D’s’’: correct diagnosis,
correct drug, appropriate dosage, and sufﬁcient duration.
First, a correct diagnosis—easily made in most patients on
the basis of the patient history and clinical examination,
and without laboratory investigations; second, the correct
drug—only a few have been proven in controlled trials to
be effective; third, an appropriate dosage—often the initial
dose is too low or too high, so that the treatment is either
ineffective or not well tolerated; and fourth, a sufﬁcient
duration—often drugs are either given for too long, such as
antivertiginous agents (e.g., dimenhydrinate), which delay
central compensation and may cause drug dependence, or
not long enough, such as in Me ´nie `re’s disease or vestibular
migraine, which require long-term treatment [8].
Depending on their etiology, vestibular disorders can be
treated with drugs, physical therapy, psychotherapeutic
measures, or rarely surgery. Before commencing treatment,
the patient should be informed that the prognosis is gen-
erally good for two reasons: (a) vertigo often takes a
favorable natural course, since peripheral vestibular func-
tion improves or central vestibular compensation of the
vestibular tone imbalance takes place; and (b) most forms
can be successfully treated (mainly with drugs or physio-
therapy). Several drugs are now available for the speciﬁc
treatment of certain vestibular and ocular motor disorders.
Peripheral vestibular disorders
Three typical forms of peripheral vestibular dysfunction
can be identiﬁed based on their characteristic symptoms
and signs: (1) acute or subacute unilateral vestibular failure
(usually acute vestibular neuritis), characterized by rota-
tional vertigo, oscillopsia, and a tendency to fall toward the
affected ear; (2) bilateral peripheral vestibular failure
(bilateral vestibulopathy), characterized by instability of
gait and posture, and oscillopsia induced by head move-
ments; and (3) paroxysmal peripheral vestibular stimula-
tion or inhibition, characterized by attacks of vertigo and
oscillopsia, occurring, for instance, in benign paroxysmal
positioning vertigo, Me ´nie `re’s disease, and vestibular
paroxysmia.
Acute vestibular neuritis
After benign paroxysmal positioning vertigo, vestibular
neuritis is the second most common cause of peripheral
vestibular vertigo. It accounts for 7% of patients presenting
to outpatient clinics that specialize in the treatment of
dizziness [2] and has an incidence of 3.5 per 100,000
population [9]. The key symptoms and signs of vestibular
neuritis include the following: an acute onset of sustained,
rotational vertigo; horizontal spontaneous nystagmus, with
a torsional component, beating toward the unaffected ear;
postural imbalance with positive Romberg’s sign (i.e., falls
toward the side of the affected ear when the eyes are
closed); and nausea and vomiting. Caloric testing usually
shows ipsilateral vestibular paresis or paralysis. Evidence
suggests that vestibular neuritis is caused by reactivation of
a latent Herpes simplex virus type 1 (HSV-1) infection.
Thus, using the polymerase chain reaction, HSV-1 DNA
has been detected on autopsy in about two of three human
vestibular ganglia [10–14]. This, as well as the expression
of CD8-positive T-lymphocytes, cytokines, and chemo-
kines, indicates that the vestibular ganglia are latently
infected with HSV-1 [15].
In a prospective, randomized, double-masked, two-by-
two factorial trial, 141 patients with acute vestibular neu-
ritis were randomly assigned to receive treatment with
placebo, methylprednisolone (100 mg/day, doses tapered
by 20 mg every fourth day), valacyclovir (1 g tid for
7 days), or methylprednisolone plus valacyclovir [16].
Vestibular function was determined by caloric irrigation,
with the use of the standard vestibular paresis formula, to
measure the extent of unilateral caloric paresis [17], within
3 days of the onset of symptoms and 12 months after-
wards. The mean improvement in peripheral vestibular
function at the 12-month follow-up was 39.6% in the pla-
cebo group, 62.4% in the methylprednisolone group, 36.0%
in the valacyclovir group, and 59.2% in the methylpred-
nisolone plus valacyclovir group. Analysis of variance
showed that methylprednisolone had a signiﬁcant effect,
but valacyclovir did not. Therefore, this study showed that
methylprednisolone alone signiﬁcantly improves the
recovery of peripheral vestibular function in patients with
vestibular neuritis, whereas valacyclovir is not effective.
However, future studies employing more detailed testing of
vestibular function might yet deﬁne a therapeutic role for
valacyclovir. All in all, this inexpensive and well-tolerated
therapy can be recommended as the drug treatment of
choice for vestibular neuritis and should be considered in
combination with other treatments that have been shown to
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cises [18–20].
Animal experiments have shown that central vestibular
compensation can be improved by several agents. A pla-
cebo-controlled clinical trial to evaluate the effects of
betahistine on central vestibular compensation was started
recently (BETAVEST, EudraCT No. 2009-013702-14).
In summary, the pharmacological treatment of choice
for acute vestibular neuritis is corticosteroids beginning
within 3 days of symptom onset (e.g., methylprednisolone
100 mg orally per day, followed by progressive tapering of
the dose).
Me ´nie `re’s disease
Me ´nie `re’s disease is characterized by recurrent spontane-
ous attacks of vertigo, ﬂuctuating hearing loss, tinnitus, and
aural fullness. Its incidence varies between 7.5 per 100,000
and 160 per 100,000 persons (for review, see [21]).
Endolymphatic hydrops is assumed to be the pathological
basis of Me ´nie `re’s disease and is thought to arise due to
either excessive production or inadequate absorption of
endolymph. The increased endolymphatic pressure causes
periodic rupturing of, or leakage from, the membrane
separating the endolymphatic from the perilymphatic space
(by the opening of nonselective, stretch-activated ion
channels [22]). Therefore, aims of treatment include
reducing the production and increasing the absorption of
endolymph. The clinical aims of treatment are to stop
vertigo attacks, reduce or abolish tinnitus, and preserve or
even reverse hearing loss. Most treatment studies have
focused on reducing the attacks of vertigo, which are the
severest symptom of Me ´nie `re’s disease.
Many treatments have been proposed for Me ´nie `re’s
disease, but almost none have been demonstrated to be
effective in controlled trials. Procedures to destroy the
lateral semicircular canal and vestibule have been proposed
since 1904. The ﬁrst endolymphatic sac decompression
was performed in 1926; this method is still used at some
centers, despite lack of demonstration of its effectiveness
[23]. Restricted salt and ﬂuid intake and the use of diuretics
were ﬁrst proposed in 1934. Salt restriction and diuretics
are still recommended, although there is no evidence for
their efﬁcacy [24, 25]. Vestibulotoxic drugs, such as ami-
noglycosides, have been used since 1948; intratympanic
injections of these agents have been performed since 1956
[26]. It is remarkable that, despite the high incidence of
Me ´nie `re’s disease and the large number of treatment
studies published in recent decades, only a few prospective,
placebo-controlled, double-masked treatment trials have
been performed. Moreover, there are signiﬁcant differences
in the treatment options offered in Europe and the US. In
the US, low-salt diet, diuretics, and intratympanic injection
of gentamicin and corticosteroids are preferred. In Europe,
betahistine is often used, whereas it is not approved for use
in the US. A national survey of UK otolaryngologists on
the treatment of Me ´nie `re’s disease revealed that 94% used
betahistine, 71% salt restriction, 63% diuretics, 52% sac
decompression, and approximately 50% insertion of an ear
tube [26]. Local gentamicin instillation has become more
popular since its introduction in the UK 10 years ago;
approximately two-thirds of British otolaryngologists now
use this method [26].
Intratympanic injections of gentamicin
Several studies have been published on the use of intra-
tympanic gentamicin for the treatment of unilateral
Me ´nie `re’s disease. Initially, the strategy was to give mul-
tiple intratympanic injections of gentamicin until patients
developed vestibular hypofunction, resulting in a reduced
frequency of vertigo attacks, but a high rate of sensori-
neural hearing loss (approximately 50%). Subsequently,
this approach was changed in two ways, especially after a
delayed onset of ototoxicity was demonstrated [27]: (1)
single instillations at ﬁxed intervals of several days or
weeks; or (2) single-shot injections with follow-up. For the
latter regimen, a prospective, uncontrolled study of 57
patients with a follow-up time of 2–4 years showed that the
vertigo attacks could be controlled in 95% of patients [28].
Fifty-three percent of patients needed only one gentamicin
injection, while 32% needed two or three injections. A
recent meta-analysis of 15 trials on gentamicin injection,
including a total of 627 patients, showed that complete
vertigo control was achieved in about 75% of patients and
complete or substantial control obtained in about 93% [29].
The success rate was not affected by the gentamicin
treatment regimen, i.e., ﬁxed versus titrated. In addition,
hearing level and word recognition was not adversely
affected, regardless of treatment regimen. However, the
authors pointed out that the level of evidence was inade-
quate due to the relatively poor study designs: none of the
trials were double-masked or had a masked prospective
control. Nonetheless, there is good evidence that the ben-
eﬁcial effect of gentamicin is due to vestibular hair cell
damage [30]. A complete ablation of function, however, is
probably not necessary in order to control the vertigo
attacks [31]; titration to the ﬁrst sign of hypofunction (e.g.,
spontaneous nystagmus or positive head-impulse test) is
sufﬁcient.
Intratympanic injections of corticosteroids
In a retrospective chart review, the effects of intratympanic
injections of dexamethasone were evaluated in 34 patients
with Me ´nie `re’s disease [32]. After a single course of
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1 month, only 24% of patients reported vertigo control.
Another 24% responded to a repeat series of injections.
Overall, control of vertigo was achieved in approximately
50% of patients with one or more courses of intratympanic
dexamethasone. The safety of intratympanic dexametha-
sone was evaluated using transient evoked otoacoustic
emissions: no change was found in 26 patients after ﬁve
4-mg injections of dexamethasone [33].
Betahistine
In Europe, betahistine is often used, mainly on the basis of
a study by Meyer [34] and more recent meta-analyses [35,
36]. Betahistine is an H1-agonist and H3-antagonist. It
improves the labyrinthine microcirculation by acting on the
precapillary sphincters of the stria vascularis [37]. There is
evidence that it reduces the production and increases the
absorption of endolymph. In an open trial of betahistine
dihydrochloride in 112 patients with Me ´nie `re’s disease, it
was shown that high-dose (48 mg tid) and long-term
treatment (12 months) were more effective than low-dose
(16–24 mg tid) and short-term treatment (Fig. 1)[ 38].
These ﬁndings are the basis for an ongoing prospective,
randomized, double-masked dose-ﬁnding study, comparing
placebo with 16 mg tid and 48 mg tid of betahistine
dihydrochloride.
In summary, the pharmacological treatment of choice
for Me ´nie `re’s disease is betahistine dihydrochloride, with a
dosage of at least 48 mg tid for at least 6–12 months [38].
Alternatively, in unilateral Me ´nie `re’s disease, gentamicin
can be administered transtympanically (20–40 mg/injec-
tion) at intervals of 4–8 weeks, depending on efﬁcacy.
Vestibular paroxysmia
Vestibular paroxysmia is characterized by short attacks of
vertigo that last for seconds to minutes, and may occur
many times a day. The attacks are usually spontaneous, but
are occasionally triggered by head-turns or hyperventila-
tion. Like trigeminal neuralgia, hemifacial spasm, and
superior oblique myokymia, it is assumed that vascular
compression of the 8th cranial nerve is the cause of ves-
tibular paroxysmia [39]. In a recent study, neurovascular
compression was found in 95% of patients and hyperven-
tilation caused attacks or nystagmus in about 70% of
patients examined [40]. Despite these new ﬁndings, this
entity remains difﬁcult to diagnose.
As demonstrated in an open trial [40], a low dose of
carbamazepine (200–600 mg/day) or oxcarbazepine
(300–900 mg/day) often gives prompt relief and, thus, may
help to establish the diagnosis. In patients who are unable
to tolerate these medications, phenytoin, valproic acid, or
acetazolamide may be effective, although there are no trial
data to conﬁrm their efﬁcacy. Currently, a prospective,
placebo-controlled, double-masked trial with oxcarbaze-
pine is being performed.
Central vestibular disorders
Vestibular migraine
Vestibular migraine is increasingly regarded as the most
common central cause of recurrent attacks of vertigo.
Characteristic features include recurrent attacks of various
combinations of vertigo, ataxia of stance and gait, photo-
phobia and phonophobia, and other brainstem symptoms,
accompanied or followed by head pressure, pain, nausea, or
vomiting [41, 42]. Treatment is the same as for migraine
with aura: beta-blockers (metoprolol or propranolol), val-
proic acid, or topiramate for at least 3–6 months. Several
treatment trials have been performed in patients with ves-
tibular migraine. Tricyclic antidepressants in combination
with diet gave a good response ([95%) in a noncontrolled
trial on 81 patients [43]. For zolmitriptan, the response rate
in acute attacks was 38 versus 22% for placebo in a study
on 19 patients [44]. Another open trial on 10 patients
demonstrated that lamotrigine (100 mg/day as a single
dose) had a signiﬁcant effect on the occurrence of headache
and a more marked effect on vertigo [45]. The treatment
options have been summarized in a retrospective study
[46]. At present, only standard treatments for migraine with
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Fig. 1 Effects of betahistine dihydrochloride [low dosage (ﬁlled
square, dotted line): 16 or 24 mg tid versus high dosage (ﬁlled
diamond, solid line): 48 mg tid] on the frequency of attacks of vertigo
in 112 Me ´nie `re’s disease patients. The mean number of attacks/month
(±SEM) during the 3 months preceding treatment (month 0) is
indicated, as well as the number/month during therapy (month 3, 6, 9,
12). After 12 months, the mean (median) number of attacks dropped
from 7.6 (4.5) to 4.4 (2.0) (p\0.0001) in the low-dosage group, and
from 8.8 (5.5) to 1.0 (0.0) (p\0.0001) in the high-dosage group. The
number of attacks after 12 months was signiﬁcantly lower in the high-
dosage group than in the low-dosage group (p12M = 0.0002) (from
[38])
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placebo-controlled, multicenter trial to evaluate the efﬁ-
cacy of metoprolol on the frequency of attacks in vestibular
migraine has been initiated (PROVEMIG EudraCT No.
2009-013701-34).
In summary, the pharmacotherapy of vestibular
migraine has not yet been evaluated with state-of-the-art
clinical trials. Consequently, only drugs that are effective
for treating migraine with and without aura can currently
be recommended. For the therapy of acute attacks, aspirin
and an antiemetic could be offered, whereas metoprolol
(100 mg/day), topiramate (50–100 mg/day), or valproic
acid (300–900 mg/day) could be offered for prophylaxis.
Episodic ataxia type 2
Episodic ataxia type 2 (EA 2) is characterized by recurrent
attacks of ataxia, often provoked by stress or exercise,
which last for several hours to days [48–50]. Clinical
ﬁndings between attacks include signs of central ocular
motor and vestibular dysfunction, in particular downbeat
nystagmus. Patients with EA 2 can often be successfully
treated with acetazolamide [51]; patients with other
inherited forms of episodic ataxia might also respond to
acetazolamide. Genetically, EA 2 is an autosomal domi-
nant disorder caused by mutations in the calcium channel
gene CACNA1A [52], which encodes the CaV2.1 subunit of
the so-called PQ-type calcium channel, which is strongly
expressed in Purkinje cells. The functional changes
induced by the PQ-type calcium channel mutation, which
result in a reduced calcium current, are thought to decrease
the inhibitory effect of Purkinje cells. This results in dis-
inhibition of the deep cerebellar nuclei and, thus, ataxia, as
well as disinhibition of vestibular nuclei neurons receiving
anterior semicircular canal pathways, leading to downbeat
nystagmus. As aminopyridines (potassium channel block-
ers) improve downbeat nystagmus (see below), their effects
on the frequency of attacks in EA 2 were also evaluated
[53]. In three patients with EA 2 who no longer responded
to standard treatment with acetazolamide (two with proven
mutations of the CACNA1A gene), 4-aminopyridine (5 mg
tid) prevented attacks. Attacks recurred after the treatment
was stopped, and reintroduction of the treatment stopped
the attacks (mean follow-up time was greater than
12 months). Based on the above-mentioned open trial, a
placebo-controlled cross-over trial has been performed,
showing that 4-aminopyridine reduces the frequency of
attacks and improves quality of life in EA 2 (paper
submitted).
Originally, it was assumed that the effects of 4-amino-
pyridine were due to increased inhibition by Purkinje cells,
a hypothesis supported by animal experiments [54]. How-
ever, recent studies on a mouse model of EA 2 show that
therapeutic concentrations of 4-aminopyridine restore the
diminished precision of pacemaking in affected Purkinje
cells, by prolonging the action potential and increasing the
action potential after-hyperpolarization [55]. The clinical
ﬁndings are supported by an animal study on the calcium
channel mutant tottering mouse; aminopyridines reduced
the frequency of attacks in the mouse by increasing the
threshold for attack initiation, without altering the charac-
ter of the attacks [56].
In summary, acetazolamide remains the pharmacologi-
cal treatment of choice for episodic ataxia type 2; a dosage
between 250 and 1,000 mg/day is usually effective,
although higher doses may be required. Acetazolamide
may cause kidney stones, requiring patient counseling of
this risk. Alternatively, 4-aminopyridine can be used with a
dosage of 5–10 mg tid.
Pathological nystagmus and saccadic intrusions
Nystagmus can be deﬁned as a repetitive, to-and-fro
movement of the eyes that is initiated by a slow phase.
Nystagmus is common with a prevalence of around 0.1%
[57], and often produces visual symptoms, such as blurred
vision or illusory motion of the visual environment
(oscillopsia) [4]. Common forms of acquired nystagmus
include gaze-evoked, downbeat, and upbeat nystagmus,
and pendular nystagmus associated with either multiple
sclerosis or the syndrome of oculopalatal tremor (OPT).
Reviewing therapies for nystagmus: downbeat and upbeat
nystagmus may respond to aminopyridines, acquired pen-
dular nystagmus to gabapentin and memantine, and peri-
odic alternating nystagmus to baclofen. Infantile
(congenital) forms of nystagmus often do not give rise to
visual symptoms, especially when the patient has well-
developed foveation periods that provide stable, clear
‘‘snapshots’’ of the world. Those patients with visual
symptoms from infantile nystagmus may beneﬁt from
memantine, gabapentin, surgical, or optical therapies [7].
To date, several clinical trials have been performed to
evaluate some pharmacological treatments for nystagmus,
but further trials are necessary to conﬁrm the efﬁcacy of
many other proposed treatments.
Gaze-evoked nystagmus is probably the most common
form of acquired nystagmus encountered in clinical prac-
tice, occurring in individuals taking a range of drugs,
including anticonvulsants, benzodiazepines, and ethanol, as
well as in patients with cerebellar disease [4]. However, it
rarely causes visual symptoms, because it is absent when
the eyes are close to center position, and rarely requires
speciﬁc treatment. Thus, gaze-evoked nystagmus will not
be considered further in this review. In the following sec-
tions, the pathophysiology and treatment of other common
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The frequencies of other forms of nystagmus and saccadic
intrusions, as seen in a specialist neurological dizziness
unit, are summarized in Table 1 [58]. However, according
to one epidemiological study, the most frequent form is
acquired pendular nystagmus, due to its high prevalence in
multiple sclerosis patients [59]. Pharmacological treat-
ments are generally the most successful means of therapy
for acquired forms of nystagmus; alternative treatment
approaches for nystagmus, such as optical devices and
surgery, are reviewed elsewhere [7]. The characteristics,
pathogenesis, and treatment of downbeat, upbeat, acquired
pendular, periodic alternating, and infantile (congenital)
forms of nystagmus are summarized in Table 2.
Downbeat nystagmus (DBN)
Downbeat nystagmus (DBN) is a common form of
acquired nystagmus (Table 1)[ 58] that is characterized by
slow upward drifts with downward quick phases. Patients
frequently report blurred vision or oscillopsia, which
increases on lateral gaze, as well as associated unsteadiness
of gait and postural imbalance [58]. DBN is usually most
prominent on lateral and downward gaze. DBN is often
inﬂuenced by convergence, sometimes with suppression [4,
60, 61], and is often associated with other ocular motor,
cerebellar, and vestibular signs, including impairment of
smooth pursuit, optokinetic nystagmus, and visual sup-
pression of the vestibulo-ocular reﬂex (VOR) [4, 62–66].
DBN has been associated with many disorders [4, 62,
64–67]. In a recent study, 117 patients were reviewed to
establish whether analysis of a large sample and improved
diagnostic testing would reduce the number of cases with
‘‘idiopathic’’ DBN in favor of speciﬁc diagnoses [58]. In
62% (n = 72) of patients, an etiology was identiﬁed
(‘‘secondary’’ DBN); common causes included cerebellar
degeneration demonstrated by CT or MRI (n = 23) and
cerebellar ischemia (n = 10). In the remaining 38%
(n = 45), no cause was found; thus, ‘‘idiopathic’’ DBN
remains common. Substantial proportions of patients with
both idiopathic and secondary DBN have associated bilateral
vestibulopathy, polyneuropathy, or cerebellar ataxia, some-
times without cerebellar abnormalities on MRI.
Three main pathophysiological mechanisms have been
proposed for DBN: (1) a tone imbalance of the central
vestibular pathways subserving vertical eye movements
[60, 62, 68, 69], including the otolithic pathways, such that
DBN is often gravity dependent [70, 71]; (2) an imbalance
of vertical smooth-pursuit tone causing spontaneous
upward drift [72]; and (3) a mismatch in the three-dimen-
sional neural coordinate system for vertical saccade gen-
eration due to a defect of the neural velocity-to-position
integrator for gaze holding [64]. Bilateral ablation of the
cerebellar ﬂocculus and paraﬂocculus in monkeys produces
DBN and a gaze-holding deﬁcit [73], as well as impaired
smooth pursuit, adaptation of the horizontal VOR [74, 75],
and visual suppression of the VOR [76]. Marti et al. [77]
proposed that the distribution of the on-directions of ver-
tical gaze-velocity Purkinje cells in the ﬂocculus is inher-
ently asymmetrical; these cells are predominantly activated
with ipsilateral and downward gaze velocities, whereas
only *10% of them show on-directions for upward gaze
velocities [78]. With functional magnetic resonance
imaging (fMRI) and 18F-ﬂuorodeoxyglucose positron
emission tomography, it was shown that patients with DBN
have diminished activation and metabolism in the ﬂocculi
(Fig. 2)[ 79, 80], supporting the view that a functional
deﬁciency of the ﬂocculi causes not only a defect in
downward pursuit, but also DBN [77]. Recent studies using
voxel-based morphometry have demonstrated atrophy in
areas of the cerebellum related to ocular motor function in
patients with DBN [79, 81].
Since the inhibitory inﬂuence of GABAergic Purkinje
cells was assumed to be impaired in DBN, several agents
that act via GABA have been investigated. Clonazepam, a
GABAA agonist, improved DBN (dosage 0.5 mg tid–1 mg
bid) in two uncontrolled studies [82, 83]. Baclofen, a
GABAB agonist, was thought to reduce DBN [84], but a
double-masked cross-over trial showed that only 1 of
6 patients with DBN responded [85]. Gabapentin, now
known to be an alpha-2-delta calcium channel antagonist,
only suppressed DBN in 1 of 6 patients in the same clinical
trial [85].
On the basis of the assumed pathophysiological mech-
anism of DBN, the effects of 3,4-diaminopyridine (3,4-
DAP) were evaluated in a randomized, controlled, cross-
Table 1 Frequency of infantile (congenital) and/or acquired ocular
oscillations in 4,854 consecutive patients who were seen in a neuro-
logical dizziness unit; patients with pure gaze-evoked nystagmus
were not included
Type of nystagmus/ocular oscillation Number
Downbeat nystagmus 101
Upbeat nystagmus 54
Central positional nystagmus 26
Pendular nystagmus 15
Infantile (congenital) nystagmus 12
Pure torsional nystagmus 12
Seesaw nystagmus 8
Ocular ﬂutter 8
Square wave jerks 7
Opsoclonus 1
Periodic alternating nystagmus 1
Downbeat nystagmus was the most frequent ﬁxation nystagmus (from
[58])
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degeneration, infarction, Chiari malformation, or unknown
etiology [86]. The mean peak slow-phase velocity of DBN
was measured before and 30 min after ingestion of 20 mg
of 3,4-DAP or oral placebo. 3,4-DAP reduced the mean
peak slow-phase velocity from 7.2 deg/s before treatment
to 3.1 deg/s 30 min after ingestion (p\0.001). The mean
peak slow-phase velocity was decreased by more than 50%
in 10 of 17 patients. Except for transient perioral or digital
paresthesia (3 patients) and nausea and headache (1
patient), no other signiﬁcant side-effects were reported.
The authors demonstrated that the single dose of 3,4-DAP
signiﬁcantly improved DBN and visual acuity, and also
reduced oscillopsia. It must be kept in mind that only 50%
of all patients with DBN respond to this treatment, mainly
those without focal lesions of the cerebellum or brainstem
[86]. These ﬁndings were supported by a more recent trial
assessing the effect of 3,4-DAP on DBN in patients with
cerebellar degeneration [87]. An effect of 3,4-DAP on the
gravity dependence of DBN is also reported [88] and those
taking 3,4-DAP often report improved balance [89]. It is
thought that aminopyridines might increase the activity and
excitability of Purkinje cells [54], thereby restoring the
physiological inhibitory inﬂuence of the vestibulo-cere-
bellum on the vestibular nuclei. More recent animal studies
have demonstrated that therapeutic concentrations of
4-aminopyridine restore the diminished precision of pace-
making in Purkinje cells [55].
The underlying mechanism of action of 4-AP in DBN
was also investigated in two studies using the magnetic
search-coil technique to make precise measurements of eye
movements [90, 91]. The major ﬁndings of these studies
were as follows: (1) 4-AP not only improved DBN, but also
improved smooth pursuit [90]; (2) 4-AP improved ﬁxation
by restoring gaze-holding ability and neural integrator
function; and (3) 4-AP may work best when DBN is
associated with cerebellar atrophy (Fig. 3)[ 91]. If DBN is
caused by a focal structural lesion, 4-AP does not improve
Table 2 Summary of the clinical features, pathophysiology, etiology, site of lesion, and current treatment options for common forms of central
nystagmus
Downbeat nystagmus (DBN) Upbeat nystagmus
(UBN)
Acquired pendular
nystagmus (APN)
Periodic alternating
nystagmus (PAN)
Infantile (congenital)
nystagmus
Direction of
nystagmus
(quick
phase)
Downward, may be diagonal
with lateral gaze
Upward Mainly horizontal, may
have vertical and/or
torsional components
Horizontal Mainly horizontal; may
have torsional and small
vertical components
Waveform
(slow
phase)
Jerk, constant, increasing, or
decreasing slow-phase
velocity
Jerk, constant,
increasing, or
decreasing slow-
phase velocity
Pendular, sinusoidal
slow-phase
Jerk, mostly constant
slow-phase
velocity
Accelerating slow-
phases; foveation
periods when the eye is
transiently still
Special
features
Increased intensity during
lateral and downward gaze;
sometimes inﬂuenced by
convergence
Increased intensity
during upward
gaze; may convert
to DBN on
convergence
Associated with other
oscillations (e.g.,
palate) and with
hypertrophic
degeneration of the
inferior olive
Changes direction
every 90–120 s
Null zone, in which
nystagmus is minimal;
often suppressed with
convergence
Sites of
lesion
Cerebellum (bilateral
ﬂoccular hypofunction);
rarely lower brainstem
lesions
Medial medulla,
ponto-
mesencephalic
junction, rarely
cerebellum
Pontomedullary,
probably affecting
components of neural
integrator for gaze
holding
Cerebellum
(nodulus, uvula)
Uncertain; some cases are
associated with afferent
visual system anomalies
Etiology Cerebellar tumors,
degenerations, Chiari
malformations, and stroke;
idiopathic; often associated
with bilateral
vestibulopathy and
neuropathy
Brainstem or
cerebellar stroke
and tumors;
Wernicke’s
encephalopathy
Multiple sclerosis,
oculopalatal tremor
due to brainstem or
cerebellar stroke
involving Guillain-
Mollaret triangle
Cerebellar
degeneration,
cranio-cervical
anomalies,
multiple sclerosis,
cerebellar tumors
and stroke
Uncertain; may be
associated with afferent
visual system
anomalies; hereditary in
some patients (e.g.,
FRMD7 mutations)
Treatment 4-Aminopyridine
(5–10 mg tid), 3,4-
diaminopyridine
(10–20 mg tid), baclofen
(5 mg tid) clonazepam
(0.5 mg tid)
Often transient,
treatment often not
necessary; baclofen
(5–10 mg tid)
4-aminopyridine
(5–10 mg tid)
Memantine
(10 mg qid)
gabapentin
(300 mg qid)
Baclofen
(5–10 mg tid)
Gabapentin (300 mg qid)
memantine (10 mg qid)
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123DBN in most cases. A PET study showed that 4-AP
increases metabolic activity in the ﬂocculus in parallel with
reducing DBN [80]. The ﬁndings of these studies support
the hypotheses for both the pathophysiological mechanism
underlying DBN and the means by which aminopyridines
might reduce it.
Based on recent studies, treatment of DBN with 4-AP
(5–10 mg tid) or 3,4-DAP (10–20 mg tid) is recommended.
Fig. 2 Activation of the
ﬂocculus (red) demonstrated,
using fMRI, in controls vs
patients for the contrast
‘‘smooth pursuit in the
downward direction’’
(SMDOWN)—‘‘ﬁxation of a
target in the middle of the
display’’ (FIXMID). Results
obtained by region of interest
group analysis are
superimposed onto orthogonal
sections (a coronal plane,
b sagittal plane, c axial plane) at
Montreal Neurological Institute
coordinates xyz =- 20, -36,
-40, through a standard brain
template (p\0.01). d Original
recording (search-coil) of
vertical pursuit (0.1667 Hz,
amplitude ± 18), which
demonstrates relatively normal
upward pursuit and impaired
downward pursuit in a patient
with DBN (from [79])
Fig. 3 Spontaneous vertical drift: vertical drift in control subjects
and DBN patients due to cerebellar atrophy (DBN I), unknown
etiology (DBN II), or other etiologies (DBN III) before (PRE) and
after (POST) administration of 4-aminopyridine (4-AP) (gray circles
target visible, black squares target blanked). DBN was reduced most
in DBN I and to a lesser extent in DBN II following treatment.
Similar effects were observed when the target is blanked. Error bars
indicate the 95% conﬁdence intervals (from [91])
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123Side-effects,morecommonwith3,4-DAP,includeseizures,if
high dosages are given, and cardiac arrhythmias. Thus, every
patientshouldhaveanECGbeforeand30 minafteringestion
ofthedrugtoconﬁrmthattheydonotdevelopprolongationof
thecorrectedQT-interval.Theeffectsofthesustained-release
form of 4-AP are yet to be evaluated.
Upbeat nystagmus
Upbeat nystagmus (UBN) present with the eyes in central
position is reported to be next most common form of
acquired nystagmus after DBN. UBN usually increases
w i t hu p g a z ea n di sa s s o c i a t e dw i t hi m p a i r e dv e r t i c a l
pursuit [4]. Convergence may suppress UBN or convert it
to DBN. UBN is most often caused by brainstem lesions
involving the ponto-mesencephalic junction and medulla;
it is sometimes associated with cerebellar disease.
Lesions in the pathways mediating upward eye move-
ments, from the vestibular and perihypoglossal nuclei, via
the ventral tegmental tract and brachium conjunctivum, to
the ocular motor nuclei, might result in the pathological
slow downward drift of the eyes seen in UBN [4, 61, 92].
Fig. 4 Examples of the vertical
components of acquired
pendular nystagmus in
association with MS (a–c) and
OPT (d–f). Representative
records are shown when the
patients were taking no
treatment for their nystagmus
(top panels), memantine 40 mg/
day (middle panels), or
gabapentin 1,200 mg/day
(bottom panels). Compare the
lower-amplitude oscillations at
one frequency (5.6 Hz) in the
patient with MS versus the
larger-amplitude oscillations at
lower, variable frequencies in
the patient with OPT. Both
drugs (especially memantine)
reduce the amplitude of the
oscillations in the MS patient
without changing their
frequency and also suppress a
superimposed upbeat
nystagmus. Both drugs
(especially gabapentin) reduce
the oscillations of OPT, which
then show more cycle-to-cycle
variation
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imbalance of vertical VOR tone or a mismatch in the
neural coordinate systems of saccade generation and
velocity-to-position integration. Affected patients with
ponto-mesencephalic brainstem lesions often have asso-
ciated unilateral or bilateral internuclear ophthalmople-
gia, indicating involvement of the medial longitudinal
fasciculus. The main diseases associated with UBN
include multiple sclerosis, brainstem stroke or tumor,
Wernicke’s encephalopathy, cerebellar degeneration, and
drug intoxications thought to be causing dysfunction of
the cerebellum [4].
UBN usually persists for several weeks, but is not per-
manent in most patients. As the slow-phase velocity of
UBN is initially high, many patients seek treatment for
disabling oscillopsia and postural instability. GABAergic
substances, such as baclofen, have been used to treat UBN,
but only have a moderate effect. One uncontrolled study
demonstrated a beneﬁcial effect of baclofen (5–10 mg tid)
[84]. A recent prospective, double-masked, cross-over
study of gabapentin and memantine demonstrated sup-
pression of UBN with memantine (10 mg qid) in 1 patient
[121]. Two other patients with upbeat components to their
nystagmus also responded to memantine [121]. In another
study, 4-AP reduced the peak slow-phase velocity in the
light from 8.6 to 2.0 /s in a single patient with UBN [93].
Since 4-AP did not affect UBN in darkness, it was con-
cluded that it reduces the downward drift in UBN by
augmenting smooth pursuit commands [94]. 4-AP may
strengthen these parallel pathways by increasing the
excitability of cerebellar Purkinje cells [54]. In summary,
most patients with UBN do not need pharmacological
treatment, because the nystagmus spontaneously settles in
most cases. If symptoms are severe or persistent, treatment
with memantine (10 mg qid) or 4-AP (5–10 mg tid) may
be effective. If these are ineffective, baclofen
(5–10 mg tid) could be tried.
Acquired pendular nystagmus
Acquired pendular nystagmus (APN) can have horizontal,
vertical, or torsional components. If the horizontal and
vertical oscillatory components are in phase, the observed
trajectory of the nystagmus will appear oblique, but if they
are out of phase, as is usually the case, the trajectory will
be elliptical or circular. The amplitude of the oscillations in
each eye may differ, so that the nystagmus appears dis-
junctive or occasionally monocular [4]. APN occurs in two
main clinical settings: (1) in association with disorders of
central nervous system myelin, especially multiple sclero-
sis (MS); and (2) as a component of the syndrome of
oculopalatal tremor (OPT), formerly known as oculopalatal
myoclonus.
APN in multiple sclerosis (MS)
In MS, the frequency of APN typically ranges from 3–5 Hz
and the oscillations are regular. Large saccades may tran-
siently stop or ‘‘reset’’ the timing (phase) of the oscilla-
tions. Patients with MS who present with APN often have
brainstem lesions involving the paramedian tracts [95],
which relay an efference copy signal of eye position to the
cerebellar ﬂocculus [96, 97] and, thereby, contribute to
gaze-holding. Although vision is often impaired in patients
with MS who have APN, impaired visual feedback does
not appear to be the cause [98]; it is more likely that APN
arises due to instability of the neural integrator, which
normally ensures steady gaze-holding [99].
Several agents have been evaluated in clinical trials of
treatment for APN in MS. Anticholinergic drugs, such as
trihexyphenidyl [100], have not proven effective and ret-
robulbar injection of botulinum toxin, evaluated in several
small series of patients [7], caused side effects such as
diplopia that were more troublesome to the patient than the
nystagmus itself. Memantine, a noncompetitive N-methyl-
D-aspartate receptor antagonist, was ﬁrst reported as
effective treatment for APN in MS in 1997 [101]. Gaba-
pentin, which blocks the alpha-2-delta subunit of calcium
channels, was also shown to be effective for this form of
nystagmus [85]. These and subsequent double-masked
studies have shown that both memantine and gabapentin
often suppress APN in MS patients, whereas baclofen does
not [85, 121, 137]. Either memantine (10 mg qid) or
gabapentin (300 mg qid) may be effective in MS patients
with APN (Fig. 4)[ 121]. The mechanism by which me-
mantine and gabapentin suppress APN in MS remains
uncertain, but current hypotheses include effects on the
neural integrator, including the cell groups of the para-
median tracts, cerebellar ﬂocculus, and medial vestibular
and prepositus hypoglossi nuclei.
APN in OPT
Ocular oscillations are a component of the syndrome of
oculopalatal tremor (OPT), with frequencies typically
ranging from 2–4 Hz. APN in OPT is distinct from APN in
MS, since the former has signiﬁcant inter-cycle frequency
variability, resulting in an irregular waveform [102].
Hypertrophic degeneration of the inferior olivary nucleus
(IO), following a lesion in the ‘‘Guillain-Mollaret trian-
gle’’, is often present in patients with OPT [103, 104]. The
Guillain-Mollaret triangle comprises connections between
the IO and deep cerebellar relay nuclei (DCN), via
climbing ﬁber axon collaterals in the inferior cerebellar
peduncle, and between the DCN and IO, via the supe-
rior cerebellar peduncle and central tegmental tract
[138]. According to the contemporary ‘‘dual-mechanism’’
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enhanced connexin gap junctions between pseudohyper-
trophied cells of IO. The electrotonic coupling results in
synchronous ﬁring of local patches of IO, which act as
pacemakers for maladaptive learning by the cerebellar
Purkinje cells [102]. Thus, the multiple frequencies and
irregular waveforms of OPT are attributed to the contri-
butions from distinct patches of IO neurons, which ﬁre at
somewhat different frequencies and trigger maladaptive
cerebellar learning.
Successful drug therapy may also provide support for
this dual-mechanism model for OPT, since gabapentin,
memantine, and some benzodiazepines, such as clonaze-
pam, may decrease the eye velocity of APN in OPT
patients (Fig. 4)[ 85, 121]. The blockade of NMDA
receptors in the IO, by both gabapentin and memantine, can
reduce synchronization at the IO and, thus, reduce the
amplitude of APN in OPT patients. Blockade of NMDA
receptors in the cerebellum—at the projection of the IO to
the DCN, at the projection of the climbing ﬁbers to Pur-
kinje cells, and pre-synaptically at Purkinje cells—
decreases the output of Purkinje cells [105]. The lack of
effect of baclofen on OPT is also supported by the ‘‘dual-
mechanism’’ hypothesis. Baclofen reduces the excitability
of premotor vestibular neurons via a GABAergic mecha-
nism; according to the dual mechanism hypothesis, APN in
OPT is generated by the IO and modulated by the output of
the cerebellar Purkinje cells, but is not due to down-stream
signal modulation by premotor neurons in the vestibular
nuclei [102]. The intersubject and intrasubject variability in
the effect of the drugs might also reﬂect different effects of
the central lesions at anatomically distinct sites in the
brainstem and cerebellum. Indeed, OPT patients usually
show signs of more than one area of involvement in the
brainstem or cerebellum [102]. From a practical point of
view, we recommend using gabapentin (300 mg qid) or
memantine (10 mg qid) as the drugs of choice for APN in
patients with MS or OPT, although some care is required
when giving memantine to MS patients, since this drug
may exacerbate symptoms [117].
Periodic alternating nystagmus
Periodic alternating nystagmus (PAN) is a spontaneous
horizontal jerk nystagmus that changes direction every
90–120 s. Affected patients complain of oscillopsia and
often turn their head in the direction of the quick phases in
order to bring their eyes to a position in the orbit where the
slow-phase velocity is minimized, thereby reducing oscil-
lopsia. The diagnosis is often missed if the patient is not
observed for long enough to detect the reversal of the
nystagmus. PAN is most often caused by cerebellar dys-
function, in particular by lesions of the more lateral
portions of the cerebellar nodulus or uvula. These lesions
alter the velocity-storage mechanism in the brainstem, as
has been shown in animal studies, and the oscillations are,
therefore, thought to arise from disinhibition of the opto-
kinetic–vestibular system [106]. The treatment of choice
for PAN is the GABAergic drug baclofen (5–10 mg tid),
which completely abolishes the nystagmus in most patients
[107, 108]. Memantine may be added, if necessary [109].
However, there have been no randomized controlled trials
of treatment for PAN, to date.
Infantile (congenital) nystagmus
Infantile (congenital) nystagmus often develops during the
ﬁrst few months of life and, thus, the term infantile nys-
tagmus is now preferred. Some cases are familial and
genetically heterogeneous with autosomal dominant,
autosomal recessive, and X-linked patterns of inheritance
reported. Importantly, some patients with infantile nys-
tagmus have mutations in the FRMD7 gene [110]. Infantile
nystagmus is predominantly horizontal (even in up- and
downgaze) and conjugate. Furthermore, it usually increases
on attempted visual ﬁxation and with anxiety, but often
suppresses with convergence. There may be a position in
the orbit (the so-called neutral or ‘‘null’’ zone) in which the
nystagmus intensity is minimal, and in which the patient
prefers to hold their eyes using an appropriate head turn.
The waveform of the nystagmus often changes in different
gaze positions and typically shows an accelerating slow-
phase proﬁle [111]. An important signature of infantile
nystagmus is the foveation period, during which the eye is
momentarily still while the fovea of the retina is steadily
pointed at the object of interest. Many patients with
infantile nystagmus, especially those with well developed
foveation periods, have no visual complaints. However,
some patients may have reduced visual acuity, oscillopsia,
or anomalies in head position with their nystagmus [112].
In a randomized, controlled, double-masked study, me-
mantine (10–40 mg/day) and gabapentin (600–2,400 mg/
day) decreased the intensity of infantile nystagmus and
brought about a small improvement in visual acuity [113].
Those patients with infantile nystagmus who show sup-
pression with convergence may be helped by wearing base-
out prisms on their glasses. A number of surgical treat-
ments have also been proposed for infantile nystagmus,
although their role in the management of this disorder is
still debated [7].
Other forms of nystagmus that impair vision
Seesaw nystagmus is a spontaneous nystagmus character-
ized by half-cycles during which one eye elevates and in-
torts, while the other depresses and extorts, as if pivoting
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consists of sinusoidal oscillations (i.e., slow phases during
both nystagmus half-cycles), and is associated with large
parasellar tumors causing bitemporal hemianopia and
congenital optic chiasm abnormalities, such as in septo-
optic dysplasia or achiasma. [114]. Pendular seesaw nys-
tagmus may arise due to loss of crossing visual information
from the temporal visual ﬁelds, thereby disrupting the
calibration of eye movements compensating for roll head
rotations, and leading to instability of gaze control. Pen-
dular seesaw nystagmus can be suppressed by alcohol [115,
116] and clonazepam [118].
Hemi-seesaw nystagmus consists of slow phases during
one half-cycle and quick phases during the other. It occurs
with rostral midbrain lesions in the vicinity of the inter-
stitial nucleus of Cajal (INC) [119], a structure that is
responsible for the integration of vertical and torsional eye
movements. Recent experimental studies in primate have
indicated that lesions just posterior to the INC cause hemi-
seesaw nystagmus [120]. Hemi-seesaw nystagmus may
improve with memantine or gabapentin in some patients
[121].
Although not clearly a form of nystagmus, superior
oblique myokymia is characterized by recurrent brief epi-
sodes of monocular oscillopsia and vertical diplopia [4]. As
for other brief disturbances of cranial nerve function, such
as vestibular paroxysmia (discussed above), it can be
relieved with carbamazepine [122] or gabapentin [123].
Saccadic disorders that impair vision
Square-wave saccadic jerks (SWJ), the most common
saccadic oscillation encountered in clinical practice, con-
sist of small saccades that take the eyes away from a ﬁx-
ation target, followed by a saccade in the opposite direction
to bring the eyes back to the target, with an intersaccadic
interval of typically 200 ms [4]. Small SWJ occur in
healthy individuals [124]. They are also encountered in
patients with cerebellar and parkinsonian diseases, espe-
cially progressive supranuclear palsy [4]. SWJ rarely
degrade vision, and are not considered further here.
In contrast, ocular ﬂutter and opsoclonus usually
degrade vision, often producing oscillopsia and dizziness.
Both consist of intermittent or continuous, uncalled-for,
back-to-back saccades without an intersaccadic interval;
the horizontal variant is known as ocular ﬂutter, whereas
the multidimensional variant is known as opsoclonus
[4]. These saccadic oscillations are usually caused by
paraneoplastic syndromes, post-infectious encephalitis,
demyelinating diseases, or an inherited disorder (e.g.,
microsaccadic oscillations [125] and limb tremor). They
may arise from autoimmune or cross-immune damage to
cerebellar Purkinje cells, brainstem saccade generators,
constituent membrane ion channels, or possible inherited
deﬁcits in membrane properties [126, 127, 130]. Since
some healthy subjects can generate saccadic oscillations,
usually with a convergence effort (voluntary nystagmus
or voluntary ﬂutter) [128, 129], it has been postulated that
an individual’s complement of ion channel subtypes in
the brainstem circuits that generate saccades might
inﬂuence their ability to voluntarily generate these
oscillations, as well as their dynamic characteristics. This
innate ability would be under genetic inﬂuence and might
explain why a relatively wide range of frequencies of
saccadic oscillations are seen across normal unrelated
individuals, whereas the frequency of voluntary nystag-
mus and saccadic oscillations is similar within families
[130].
A mechanism intrinsic to the membranes of saccadic
burst generators might explain the high frequency and
familial dependence of saccadic oscillations [130].
According to this hypothesis, the saccadic oscillations
represent unmasking of the inherent instability in the
saccadic burst neuron circuit due to an imbalance between
burst neuron excitability and external inhibition. It was
proposed that increased excitability of the burst neurons or
reduced external inhibition would result in increased
amplitude of the post-inhibitory rebound (PIR)—a rebound
increase in neuronal membrane discharge after sustained
membrane hyperpolarization. In a neuromimetic model of
the burst neurons, increased maximal conductance through
pacemaker ion channels, including hyperpolarization-acti-
vated, inward-mixed, cation currents (Ih), and low thresh-
old calcium currents (IT), determined the neural
excitability and the amplitude of the PIR [131]. Subse-
quently, it was hypothesized that increases in neural
excitability and/or in PIR due to pathologically increased
Ih and/or IT reduce the effects of external inhibition, so
that saccadic oscillations can emerge.
The membrane mechanism of saccadic oscillations is
supported by a number of case reports on rare etiologies of
saccadic oscillations or reports of successful treatment of
saccadic oscillations with ion channels blockers. For
example, carbamazepine, a calcium channel blocker [132],
may ameliorate saccadic oscillations. Saccadic oscillations
in patients abusing cocaine or with strychnine poisoning
[4] could be explained by reduction in norepinephrine re-
uptake, causing increases in norepinephrine-induced Ih
conductance [133]. Saccadic oscillations in hyperammo-
nemic, uremic, and hyperosmolar states could be due to
alterations in pH, which in turn regulates the maximal Ih
conductance [134]. Organophosphate-induced opsoclonus
is possibly the result of cholinergic excess causing
increased activation of the fastigial nucleus, a component
of a feedback loop of the brainstem saccade generator,
causing hyperexcitability of the saccadic burst generators
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explain saccadic oscillations in these patients [136].
Conclusions and future perspectives
Considerable progress has been made over recent decades
in describing the clinical characteristics of different forms
of nystagmus, as well as their pathophysiology and etiol-
ogy. However, the pathophysiological mechanisms under-
lying many forms of nystagmus are not well understood
and, consequently, targeted treatments have not yet been
developed. Indeed, most proposed treatments for nystag-
mus are yet to be validated in prospective, masked, ran-
domized, placebo-controlled trials. Due to the rarity of
many forms of nystagmus, multicenter trials are required
to evaluate an adequate number of patients. Several
drugs could be potentially effective (listed in alphabetical
order): acetazolamide, aminopyridines, anticholinergics
(benztropine, scopolamine, trihexyphenidyl), baclofen,
barbiturates, benzodiazepines, canabinoids, carbamazepine,
gabapentin, lamotrigine, memantine, phenytoin, selective
potassium channel blockers, selective serotonin re-uptake
inhibitors,tricyclicantidepressants,topiramate,triptans,and
valproic acid. Knowledge of the possible effects of these
agents—most of which act speciﬁcally on certain receptors
or ion channels—will also further improve our insights into
the pathophysiology of the underlying disorders and how
to treat them.
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